Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial

Neurology

Volumn 79, Issue 8, 2012, Pages 785-792

  Coelho, Teresa ^a   Maia, Luis F ^b   Da Silva, Ana Martins ^a   Cruz, Marcia Waddington ^c   Planté Bordeneuve, Violaine ^d   Lozeron, Pierre ^e   Suhr, Ole B ^f   Campistol, Josep M ^g   Conceição, Isabel Maria ^h   Schmidt, Hartmut H J ⁱ   Trigo, Pedro ^j   Kelly, Jeffery W ^k   Labaudinière, Richard ^l   Chan, Jason ^m   Packman, Jeff ^l   Wilson, Amy ^l   Grogan, Donna R ^l  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HENRI MONDOR HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f UMEÅ UNIVERSITY   (Sweden)

^g HOSPITAL CLÍNIC   (Spain)

^h HOSPITAL DE SANTA MARIA   (Portugal)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j FLENI   (Argentina)

^k SCRIPPS RESEARCH INSTITUTE   (United States)

^l PFIZER INC   (United States)

^m Kinetic Concepts Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN; TAFAMIDIS;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUTRITIONAL ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 84862222705     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182661eb1     Document Type: Article

References (32)

1. Hund E, Linke RP, Willig F, Grau A. Transthyretin-associated neuropathic amyloidosis: pathogenesis and treatment. Neurology 2001;56:431-435.
2. Benson MD. The hereditary amyloidoses. Best Pract Res Clin Rheumatol 2003;17:909-927.
3. Planté-Bordeneuve V, Lalu T, Misrahi M, et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 1998;51:708-714.
4. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88-98.
5. Blake CC, Geisow MJ, Swan ID, Rerat C, Rerat B. Structure of human plasma prealbumin at 2.5 A resolution: a preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 1974;88:1-12.
6. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 1995;268:1039-1041.
7. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(suppl 4):16427-16432.
8. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160-184.
9. Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun 2000;270:1024-1028.
10. Koike H, Misu K, Sugiura M, et al. Pathology of early-vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004;63:129-138.
11. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242-246.
12. Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl 2009;15:1229-1235.
13. Winkler M, Brinkmann C, Jost U, Oldhafer K, Ringe B, Pichlmayr R. Long-term side effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994;26:2679-2682.
14. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-716.
15. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629-9634.
16. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49:229-239.
17. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005;7:497-508.
18. Dyck PJ, Litchy WJ, Daube JR, Harper CM, Davies J, O'Brien PC. Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairment. Muscle Nerve 2003;27:202-210.
19. Dyck PJ, O'Brien PC, Litchy WJ, Harper CM, Klein CJ. Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care 2005;28:2192-2200.
20. Wang L, Packman J, Labaudinière R, Bulawa C. Novel immunoturbidimetric method to monitor transthyretin (TTR) stability in plasma. Amyloid 2006;13:67.
21. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000;284:2215-2221.
22. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-482.
23. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010;9:921-929.
24. Kim DH, Zeldenrust SR, Low PA, Dyck PJ. Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy. Muscle Nerve 2009;40:363-370.
25. Coelho T, Merkies I, Vinik A, et al. Relationship between objective measures of neuropathy and quality of life in stages of severity of transthyretin familial amyloid polyneuropathy. Amyloid 2010;17(suppl 1):138.
26. Arezzo JC. The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 1997;21:13-23.
27. Drent G, Graveland CW, Hazenberg BP, Haagsma EB. Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. Amyloid 2009;16:133-141.
28. Jonsén E, Suhr O, Athlin E, Wikström L. Quality of life after liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1996;3:124-129.
29. Jonsen E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid 2001;8:52-57.
30. Telles-Correia D, Cortez-Pinto H, Barbosa A, Mega I, Monteiro E. Quality of life following liver transplantation: a comparative study between familial amyloid neuropathy and liver disease patients. BMC Gastroenterol 2009;9:54.
31. Suhr OB, Holmgren G, Steen L, et al. Liver transplantation in familial amyloidotic polyneuropathy: follow-up of the first 20 Swedish patients. Transplantation 1995;60:933-938.
32. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479-485.